Nanoligent aim is the research and development to clinical phases of innovative cancer treatments based on protein nanoparticles.
Nanoligent has raised $14.1M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Nanoligent's investors include Inveready, CDTI Innovación's INNVIERTE program, IAG Capital Partners, Italian Angels for Growth, i&i Biotech Fund.
Nanoligent is headquartered in Barcelona, Spain.
Nanoligent aim is the research and development to clinical phases of innovative cancer treatments based on protein nanoparticles.
Nanoligent is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nanoligent — Funding & Investors." VCBacked, October 6, 2025, https://www.vcbacked.co/company/nanoligent. Accessed November 13, 2026.
VCBacked. (2025). Nanoligent — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/nanoligent
{{cite web |title=Nanoligent — Funding & Investors |url=https://www.vcbacked.co/company/nanoligent |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Nanoligent? Request a listing update